Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
-
Publication number: 20140243364Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.Type: ApplicationFiled: February 27, 2014Publication date: August 28, 2014Applicant: Pfizer IncInventors: Gary Robert Agisim, Robert Alan Friedline, Shivangi Vijaykumar Patel, César Iván Sertzen, Vanessa Rose Shepperson
-
Publication number: 20140242169Abstract: The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol Hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (GABA) analogue. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a slow release Tapentadol Hydrochloride and a therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (GABA) analogue.Type: ApplicationFiled: May 13, 2014Publication date: August 28, 2014Applicant: GRUENENTHAL GMBHInventor: RAMESH SESHA
-
Publication number: 20140242177Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.Type: ApplicationFiled: October 19, 2012Publication date: August 28, 2014Applicant: NOVA SOUTHEASTERN UNIVERSITYInventors: Mutasem Rawas-Qalaji, Keith Simons, Estelle Simons, Ousama Rachid
-
Publication number: 20140242151Abstract: The present invention provides an adhesive skin patch that permits excellent and prolonged percutaneous absorption of tulobuterol and that can be stably applied to the skin for a long period of time with less skin irritation. The adhesive skin patch comprises a base material and a medicated layer provided on one surface of the base material. The medicated layer contains 1 to 30% by weight of a resolvent, 40 to 98% by weight of a pressure-sensitive adhesive, and tulobuterol. The resolvent contains an aliphatic alcohol having a branched-chain structure or a double bond in its C8 to C30 carbon chain. The pressure-sensitive adhesive is a copolymer obtained by copolymerizing monomers containing 70% by weight or more of an alkyl(meth)acrylate whose alkyl group has 6 to 20 carbon atoms.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: Sekisui Chemical Co., Ltd.Inventors: Hiroko UDAGAWA, Toshikazu KOMODA, Masaru HAMABE
-
Patent number: 8815292Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).Type: GrantFiled: April 27, 2010Date of Patent: August 26, 2014Assignee: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20140235610Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.Type: ApplicationFiled: December 5, 2013Publication date: August 21, 2014Inventors: Yves-Alain BARDE, Graeme BILBE, Ruben DEOGRACIAS, Rainer R. KUHN, Tomoya MATSUMOTO, Anis Khusro MIR, Anna Svenja SCHUBART
-
Publication number: 20140230812Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).Type: ApplicationFiled: October 12, 2012Publication date: August 21, 2014Applicant: Mexichem Amanco Holdings S.A. de C.V.Inventors: Stuart Corr, Timothy James Noakes
-
Publication number: 20140228402Abstract: The invention relates to a combination which comprises fingolimod and at least antidepressant compound.Type: ApplicationFiled: September 7, 2012Publication date: August 14, 2014Applicant: Novartis AGInventors: Matthias Meergans, Ferenc Tracik, Katrin Schuh
-
Publication number: 20140228391Abstract: An anise flavored liquid medication. The liquid medication contains phenylephrine and an anethole analog that is substantially free of aldehyde groups. In one example, the anethole analog can be 1-methoxy-4-n-propylbenzene.Type: ApplicationFiled: February 13, 2014Publication date: August 14, 2014Applicant: The Procter & Gamble CompanyInventors: Allyn Michael Kaufmann, James Carl Grimm, Chelsay Lynn Brewster, Thomas Edward Huetter
-
Publication number: 20140228380Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.Type: ApplicationFiled: August 2, 2013Publication date: August 14, 2014Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Sandhya Kortagere, Eldo V. Kuzhikandahil
-
Publication number: 20140228443Abstract: Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.Type: ApplicationFiled: February 7, 2014Publication date: August 14, 2014Applicant: Acucela Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Feng Hong, Ryo Kubota, Jennifer Gage
-
Publication number: 20140228446Abstract: The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.Type: ApplicationFiled: April 21, 2014Publication date: August 14, 2014Inventors: Peter C. Hiestand, Christian Schnell
-
Publication number: 20140227358Abstract: The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Applicant: NOVARTIS AGInventors: Michael AMBUHL, Jutta BEYER, Begona CARRENO-GOMEZ, Colleen RUEGGER, Stephen VALAZZA
-
Publication number: 20140228355Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.Type: ApplicationFiled: February 11, 2013Publication date: August 14, 2014Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventors: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, University of Medicine and Dentistry New Jersey Medical School
-
Publication number: 20140228445Abstract: The present invention relates to alkyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 11, 2014Publication date: August 14, 2014Applicant: Allergan, Inc.Inventors: Wenkui K. Fang, Ken Chow, Evelyn G. Corpuz, Wha Bin Im
-
Patent number: 8802128Abstract: Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.Type: GrantFiled: July 21, 2006Date of Patent: August 12, 2014Assignee: Allergan, Inc.Inventors: Michael R. Robinson, Scott M. Whitcup
-
Publication number: 20140221426Abstract: Presystemic metabolism in intestine of bioactives such as phenylephrine is avoided by administering a subject (human or animal) the bioactive (e.g., phenylephrine) in combination with one or more inhibitors of sulfation (e.g., sulfotransferase enzymes aka SULTs). This can also be enhanced be co-administering inhibitors of monoamine oxidases aka, MAOs, and uridine diphosphate glucoronysl transferases, aka UGTs. Preferably the inhibitors are GRAS compounds. The one or more inhibitor compounds inhibit the enzymes responsible for rapid presystemic metabolism, thus allowing the bioactives (e.g., phenylephrine) to be more readily absorbed intact into the circulatory system.Type: ApplicationFiled: September 27, 2012Publication date: August 7, 2014Inventors: Phillip M. Gerk, William H. Barr, Joseph K. Ritter
-
Publication number: 20140221498Abstract: The present invention relates to amino diol derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 4, 2014Publication date: August 7, 2014Applicant: ALLERGAN, INC.Inventors: Wenkui K. Fang, Ken Chow
-
Publication number: 20140213617Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.Type: ApplicationFiled: January 23, 2014Publication date: July 31, 2014Applicant: ACUCELA INC.Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
-
Publication number: 20140200516Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II; aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: March 18, 2014Publication date: July 17, 2014Applicant: ABBOTT LABORATORIESInventor: Harry A. DUGGER, III
-
Publication number: 20140199382Abstract: The present invention relates to a stable pharmaceutical composition comprising an S1P receptor agonist and one or more pharmaceutically acceptable excipients, wherein the composition is free of a sugar alcohol. It also relates to method of preparing such compositions and using those compositions in the treatment of multiple sclerosis.Type: ApplicationFiled: January 10, 2014Publication date: July 17, 2014Applicant: Cadila Healthcare LimitedInventors: SUSHRUT KRISHNAJI KULKARNI, AJAYKUMAR HANDA, PRUDHVI RAJU DANTULURI
-
Patent number: 8771744Abstract: The invention provides a process for increasing the crystallinity of at least one solid material which is less than 100% crystalline, comprising applying ultrasound to the substantially dry solid material.Type: GrantFiled: October 20, 2010Date of Patent: July 8, 2014Assignee: Prosonix LimitedInventors: Graham Ruecroft, Dipesh Parikh
-
Publication number: 20140187644Abstract: The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200®. The invention also relates to processes for making such compositions.Type: ApplicationFiled: March 1, 2014Publication date: July 3, 2014Inventors: MUNISH TALWAR, RITESH KAPOOR, MANOJ MASHALKAR, GIRISH KUMAR JAIN
-
Publication number: 20140186341Abstract: The present disclosure provides methods for improving drug efficacy in a patient having an obstructed airway in a lung. Such methods modulate nerve activity in the autonomic nervous system of a patient to reduce obstruction of an airway in a lung of the patient prior to administering a drug to the patient. These methods are especially useful in improving efficacies of bronchodilators in treating obstructive lung diseases, such as chronic obstructive pulmonary disease.Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Inventor: Martin L. Mayse
-
Publication number: 20140187516Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: NOVARTIS AGInventors: Craig BOULTON, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER
-
Publication number: 20140187645Abstract: This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding ?2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Applicant: The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Irving William Wainer, Weizhong Zhu, Khalid Chakir, Rui-Ping Xiao, Darrel R. Abernethy, Farideh M. Beigi-Abhari
-
Publication number: 20140178473Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.Type: ApplicationFiled: October 11, 2013Publication date: June 26, 2014Applicant: IX BIOPHARMA PTE LTDInventors: Chin Beng Stephen LIM, Vivian Bruce SUNDERLAND, Yip Hang Eddy LEE
-
Publication number: 20140162987Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20140161903Abstract: The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.Type: ApplicationFiled: February 12, 2014Publication date: June 12, 2014Applicant: ACIEX THERAPEUTICS, INC.Inventors: Matthew J. Chapin, Mark Barry Abelson, Keith Jeffrey Lane, Akimitsu Makino
-
Publication number: 20140162988Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Patent number: 8747813Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: GrantFiled: March 6, 2013Date of Patent: June 10, 2014Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Publication number: 20140147506Abstract: Pharmaceutically engineered aerosols (e.g. submicrometer and nano-particles and droplets) containing a hygroscopic growth excipient or agent are employed to improve the delivery of respiratory aerosols to the lung. Inclusion of the hygroscopic agent results in near zero depositional loss in the nose-mouth-throat regions and near 100% deposition of the aerosol in the lung. Targeting of the aerosol to specific lung depths is also possible. In addition, methods and apparatuses for delivering aerosols to the lung are provided. The aerosol is delivered to one nostril of a patient while a relatively high humidity gaseous carrier is delivered to the other nostril, resulting in post-nasopharyngeal growth of the aerosol to a size that promotes deposition in the lung.Type: ApplicationFiled: January 29, 2014Publication date: May 29, 2014Applicant: Virginia Commonwealth UniversityInventors: Philip Worth Longest, Michael Hindle
-
Publication number: 20140148398Abstract: Compounds useful for the treatment of giardiasis are described.Type: ApplicationFiled: October 12, 2011Publication date: May 29, 2014Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
-
Publication number: 20140142192Abstract: The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: Novartis AGInventors: Colleen RUEGGER, Michael AMBUHL
-
Publication number: 20140128415Abstract: A excipient drug composition is disclosed. The excipient drug composition may include a vegetable cellulose or a fruit cellulose, an active ingredient and a genetically modified organism free starch. The vegetable cellulose or fruit cellulose may be derived from wood free vegetable pulp and the fruit cellulose is a wood pulp free cellulose. The genetically modified organism free starch may be selected from the group consisting of a genetically modified organism free rice starch, a genetically modified organism free potato starch or a genetically modified organism free pea starch.Type: ApplicationFiled: January 8, 2014Publication date: May 8, 2014Inventor: Paul Daniel Yered
-
Publication number: 20140128353Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: Biocopea LimitedInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Patent number: 8716349Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.Type: GrantFiled: March 30, 2011Date of Patent: May 6, 2014Assignee: Algynomics Inc.Inventors: Luda Diatchenko, William Maixner
-
Patent number: 8715706Abstract: A device for drug delivery to an orifice of a subject, comprising a shell which is elastically stressed by an active pharmaceutical ingredient, said shell containing and being substantially impermeable to said active pharmaceutical ingredient, wherein said shell has at least one hole sized for in-vivo release of said active pharmaceutical ingredient as a result of elastic stressing.Type: GrantFiled: June 17, 2010Date of Patent: May 6, 2014Assignee: RDD Pharma, Ltd.Inventor: Nir Barak
-
Patent number: 8716348Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: GrantFiled: March 21, 2011Date of Patent: May 6, 2014Assignee: Dey Pharma, L.P.Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
-
Patent number: 8716350Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.Type: GrantFiled: March 14, 2013Date of Patent: May 6, 2014Assignee: Algynomics Inc.Inventors: Luda Diatchenko, William Maixner
-
Publication number: 20140121234Abstract: The invention relates to inhalant propellant-free aerosol formulations containing at least one inert, non-volatile auxiliary substance for adjusting defined droplet sizes.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Christoph KREHER, Michael SPALLEK
-
Patent number: 8703826Abstract: This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding ?2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease.Type: GrantFiled: December 21, 2011Date of Patent: April 22, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: Irving W. Wainer, Weizhong Zhu, Khalid Chakir, Rui Ping Xiao, Darrell R. Abernethy, Farideh M. Beigi
-
Patent number: 8703193Abstract: The present invention relates to controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof. The controlled porosity osmotic pump tablets do not need to be drilled by laser, but provides controlled porosity for drug release by adding a suitable quantity of pore-forming agents into the semipermeable membrane. In specific embodiments, the present invention relates to controlled porous osmotic pump tablets comprising venlafaxine or metoprolol or pharmaceutically acceptable salts thereof.Type: GrantFiled: October 16, 2007Date of Patent: April 22, 2014Assignee: Cosci Med-Tech Co. Ltd.Inventors: Jingang Wang, Haisong Jiang
-
Publication number: 20140105959Abstract: Methods and devices of aesthetically enhancing and improving appearance of aging skin are provided. Methods may include the steps of treating a skin site selected for dermal filler administration with a mechanism effective to enhance drug delivery across the skin, applying to the treated site, a device, compound or formulation including an active agent effective to reduce visible bruising due to administration of a dermal filler into the site, and administering a dermal filler into the skin site thereby reduce the appearance of wrinkles or folds in the skin site without causing significant bruising. Devices for reducing or ameliorating adverse events from dermal filler administration are also included.Type: ApplicationFiled: October 10, 2013Publication date: April 17, 2014Applicant: ALLERGAN, INC.Inventors: Sumit Paliwal, Dennis Van Epps
-
Publication number: 20140107024Abstract: The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog.Type: ApplicationFiled: December 19, 2013Publication date: April 17, 2014Applicant: Diapin Therapeutics LLCInventor: Zhongmin Ma
-
Publication number: 20140100195Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: October 5, 2012Publication date: April 10, 2014Inventors: Richard D. Caldwell, Kevin M. GUCKIAN, Gnanasambandam KUMARA VEL, Wen-Cherng LEE, Edward Yin-Shiang LIN, Xiaogao LlU, Bin MA, Daniel M. SCOTT, Zhan SHl, Jermaine THOMAS, Arthur G. TAVERAS, Guo Zhu ZHENG
-
Patent number: 8691877Abstract: Methods for treating a disease condition in a subject are provided. The subject methods are characterizing by enhancing at least one symptom of the disease condition in a manner effective to cause the subject to mount a compensatory response effective to treat the disease condition. Also provided are compositions, kits and systems for practicing the subject methods.Type: GrantFiled: October 14, 2005Date of Patent: April 8, 2014Assignee: Palo Alto InvestorsInventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Publication number: 20140094444Abstract: The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P1/S1P3 activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase microvascular remodeling. S1P3 expression on marrow-derived cells was essential for this remodeling. Concurrent systemic S1P3 and CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) with the ability to engraft and repopulate blood cells. Pre-treatment of donor HSCs with FTY720 increased homing toward SDF-1 and improved engraftment in marrow. FTY720-coated bone allografts coupled with systemic administration of VPC01091 enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand.Type: ApplicationFiled: March 16, 2012Publication date: April 3, 2014Applicant: University of Virginia Patent FoundationInventors: Edward A. Botchwey, III, Mary J. Laughlin, Kevin R. Lynch, Anusuya Das, Anthony Awojoodu
-
Publication number: 20140094522Abstract: Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided.Type: ApplicationFiled: December 5, 2013Publication date: April 3, 2014Applicant: NOVARTIS AGInventors: Thitiwan Buranachokpaisan, Rose-Marie Dannenfelser, Ping Li
-
Publication number: 20140093577Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.Type: ApplicationFiled: October 3, 2013Publication date: April 3, 2014Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Paul Taskey, Daniel Lockhart, Russell McMahen